Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +50

Regeneron (REGN) Surpasses Q1 Earnings and Revenue Estimates

AI-generated analysis

📈 Regeneron reported Q1 earnings of $9.47 per share, beating the consensus estimate of $8.52 and exceeding last year's adjusted earnings of $8.22.

💰 The company delivered an 11.18% earnings surprise, following a previous quarter with an 8.33% beat after initially missing a prior expectation of $10.56.

📊 Revenue for the quarter ended March 2026 was $3.61 billion, surpassing the consensus estimate by 4.88% compared to $3.03 billion a year ago.

✅ Over the last four quarters, Regeneron has topped consensus estimates for earnings per share and revenue four times in succession.

📉 Shares have underperformed the market this year, losing about 5.2% versus the S&P 500's gain of 4.3%.

🔮 Near-term stock performance will largely depend on management commentary from the upcoming earnings call.

🎯 The Zacks Rank for the stock is currently #3 (Hold), suggesting shares are expected to perform in line with the market.

💸 Current consensus expectations project $10.52 EPS and $3.81 billion in revenue for the coming quarter, plus $44.80 EPS and $15.51 billion for the fiscal year.

🔬 Regeneron belongs to the Zacks Medical - Biomedical and Genetics industry, which is currently ranked in the bottom 40% of all industries.

📉 Research indicates that top-ranked industries outperform the bottom half by a factor of more than 2 to 1.

⏳ Peer company Iovance Biotherapeutics (IOVA) is expected to report earnings on May 7 following Regeneron's release.

❌ Analysts anticipate a quarterly loss of $0.19 per share for Iovance, representing a year-over-year improvement of 47.2%.

💹 Iovance's revenue is forecast at $77.11 million, which would be up 56.3% from the same quarter last year.

📉 The consensus EPS estimate for Iovance has been revised 18.2% lower over the past 30 days.

📰 Zacks Investment Research provides free stock analysis reports and a list of top-ranked stocks for investors.

Bullish Signals
  • Regeneron (REGN) reported quarterly earnings of $9.47 per share, surpassing the Zacks Consensus Estimate of $8.52 per share.
  • This strong performance represents an earnings surprise of +11.18%, exceeding expectations for both current and previous quarters.
  • The company posted revenues of $3.61 billion for the quarter ended March 2026, beating consensus estimates by 4.88%.
  • Regeneron has topped consensus revenue estimates four times over the last four quarters, demonstrating consistent strong execution.
  • Earnings per share grew to $9.47 from $8.22 per share a year ago, showing meaningful year-over-year growth.
  • The company is part of the Zacks Medical - Biomedical and Genetics industry and maintains a robust financial track record.
Risk Factors
  • Regeneron shares have underperformed the broader market, losing about 5.2% since the beginning of the year while the S&P 500 gained 4.3%.
  • Ahead of this earnings release, estimate revisions for Regeneron were mixed, leading to a Zacks Rank #3 (Hold), which suggests expected performance in line with the market rather than outperformance.
  • Regeneron's industry, Medical - Biomedical and Genetics, is currently ranked in the bottom 40% of 250 plus industries, whereas research shows top industries outperform bottom ones by more than 2 to 1.
  • Competition within the sector may intensify given that peer company Iovance Biotherapeutics (IOVA) expects quarterly losses of $0.19 per share in its upcoming report.
Full Analysis
Regeneron Pharmaceuticals, Inc. reported quarterly earnings of $9.47 per share for the quarter ended March 2026, surpassing the Zacks Consensus Estimate of $8.52 per share and reflecting an adjusted annualized surprise of +11.18%. This performance compares favorably to the previous year's adjusted earnings of $8.22 per share. The biopharmaceutical company also posted quarterly revenues of $3.61 billion, exceeding the consensus estimate by 4.88% compared to the same period last year's $3.03 billion in revenue. This marks the fourth consecutive quarter that Regeneron has exceeded both earnings and revenue estimates, with the stock belonging to the Zacks Medical - Biomedical and Genetics industry having topped expectations four times over the last four quarters. Despite this strong quarterly performance, Regeneron shares have underperformed the broader market, declining approximately 5.2% since the beginning of the year compared to the S&P 500's gain of 4.3%. Analysts indicate that the sustainability of future stock price movement will largely depend on management's commentary during the earnings call and how investors interpret these figures alongside current consensus earnings expectations. Ahead of this earnings release, estimate revisions for Regeneron were mixed, leading to a Zacks Rank #3 (Hold) rating, which suggests shares are expected to perform in line with the market in the near future. Looking ahead, the current consensus EPS estimate for the coming quarter stands at $10.52 on $3.81 billion in revenues, while the full fiscal year estimate is set at $44.80 on $15.51 billion in revenues. Investors should note that the outlook for the Medical - Biomedical and Genetics industry could have a material impact on Regeneron's performance, with the Zacks Industry Rank currently placing the sector in the bottom 40% of all tracked industries. Historical research indicates that stocks in the top 50% of ranked industries tend to outperform the bottom 50% by a factor of more than two to one, suggesting potential industry-related headwinds or opportunities for investors analyzing long-term prospects beyond immediate earnings beats.